updates from the phase i/ii bruin study: pirtobrutinib in cll
Published 2 years ago • 123 plays • Length 2:39Download video MP4
Download video MP3
Similar videos
-
2:11
latest updates from the phase i/ii bruin study
-
1:51
updates on the phase i/ii bruin study and the role of pirtobrutinib in mcl
-
1:55
update on the phase i/ii bruin study
-
1:56
updated results of phase i/ii bruin study: pirtobrutinib in covalent btk inhibitor pretreated mcl
-
2:34
bruin study update: analysis of the mechanisms of resistance to pirtobrutinib in cll
-
2:25
results from a phase i/ii trial of pirtobrutinib and lv20.19 for patients with r/r lymphomas
-
5:00
venetoclax-obinutuzumab is superior to chemoimmunotherapy in frontline cll: updates from gaia/cll13
-
4:19
cll: what is 'watch & wait' and what can a patient do during this phase?
-
4:51
the current frontline treatment strategy in multiple myeloma
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
17:23
updates in cll: key clinical trials in the frontline and r/r setting, pre-clinical data and mrd
-
1:43
some insights into bruin cll-322: a trial in progress
-
2:58
results of a phase ib study of ibrutinib obinutuzumab in r/r cll
-
1:32
an update from bellwave-001: nemtabrutinib in cll/sll
-
3:05
updates on the phase i study of ft-4202 for scd
-
1:44
updates from the phase ii animate trial of nivolumab in r/r chl
-
1:18
updates from current cll clinical trials
-
6:43
key highlights in cll: clinical trial updates & the role of combination therapies and novel btkis
-
2:00
update of a phase i trial investigating lintuzumab-ac225 plus venetoclax in r/r aml
-
2:59
clinical trial updates and time-limited therapy in cll
-
1:18
the impact of the approval of pirtobrutinib on the treatment landscape for patients with cll